{"organizations": [], "uuid": "d6dbf6fc3d64842c8391176d270c9404642f379d", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-united-therapeutics-to-acquire-ste/brief-united-therapeutics-to-acquire-steadymed-ltd-idUSASC09Y5C", "country": "US", "domain_rank": 408, "title": "BRIEF-United Therapeutics To Acquire SteadyMed Ltd", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-30T13:12:00.000+03:00", "replies_count": 0, "uuid": "d6dbf6fc3d64842c8391176d270c9404642f379d"}, "author": "", "url": "https://www.reuters.com/article/brief-united-therapeutics-to-acquire-ste/brief-united-therapeutics-to-acquire-steadymed-ltd-idUSASC09Y5C", "ord_in_thread": 0, "title": "BRIEF-United Therapeutics To Acquire SteadyMed Ltd", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "brief-united therapeutics to acquire steadymed ltd", "sentiment": "negative"}, {"name": "brief-united therapeutics to acquire steadymed ltd reuters", "sentiment": "negative"}, {"name": "united therapeutics", "sentiment": "none"}, {"name": "united therapeutics-transaction", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 15 AM / Updated 6 minutes ago BRIEF-United Therapeutics To Acquire SteadyMed Ltd Reuters Staff\n SteadyMed Ltd : * UNITED THERAPEUTICS TO ACQUIRE STEADYMED LTD.\n* UNITED THERAPEUTICS-TRANSACTION, INCLUDING $75 MILLION IN CONTINGENT CONSIDERATION, IS VALUED AT $216 MILLION\n* STEADYMED LTD - UNITED THERAPEUTICS WILL ACQUIRE STEADYMED FOR $4.46 PER SHARE IN CASH AT CLOSING\n* UNITED THERAPEUTICS-WILL ALSO PAY AN ADDITIONAL $2.63 PER SHARE IN CASH UPON A MILESTONE RELATED TO COMMERCIALIZATION OF TREVYENT\n* STEADYMED LTD - STEADYMED SHAREHOLDERS OWNING ABOUT 43.3 PERCENT OF STEADYMED ORDINARY SHARES ENTERED AGREEMENT TO VOTE THEIR SHARES IN FAVOR OF DEAL Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-04-30T13:12:00.000+03:00", "crawled": "2018-04-30T13:26:05.002+03:00", "highlightTitle": ""}